Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
NASDAQ:FBIO

Fortress Biotech - FBIO Stock Forecast, Price & News

$0.72
-0.01 (-1.36%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.71
$0.76
50-Day Range
$0.68
$0.98
52-Week Range
$0.67
$2.98
Volume
28,943 shs
Average Volume
127,249 shs
Market Capitalization
$78.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

Fortress Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,210.3% Upside
$9.50 Price Target
Short Interest
Healthy
0.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$69,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.82) to ($0.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

145th out of 1,044 stocks

Pharmaceutical Preparations Industry

66th out of 510 stocks

FBIO stock logo

About Fortress Biotech (NASDAQ:FBIO) Stock

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Stock News Headlines

See More Headlines
Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Company Calendar

Last Earnings
11/15/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FBIO
CUSIP
21976U10
Employees
173
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.50
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+1,210.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-64,700,000.00
Net Margins
-117.49%
Pretax Margin
-289.25%

Debt

Sales & Book Value

Annual Sales
$68.79 million
Book Value
$0.94 per share

Miscellaneous

Free Float
79,401,000
Market Cap
$78.11 million
Optionable
Optionable
Beta
1.92

Key Executives

  • Dr. Lindsay Allan Rosenwald (Age 67)
    Exec. Chairman, Pres & CEO
    Comp: $92.65k
  • Mr. Michael S. Weiss Esq. (Age 56)
    Vice Chairman & Exec. Vice Chairman of Strategic Devel.
    Comp: $92.65k
  • Dr. George C. Avgerinos (Age 68)
    Sr. VP of Biologics Operations
    Comp: $524.35k
  • Ms. Robyn M. Hunter (Age 60)
    Exec. Officer
    Comp: $555.31k
  • Mr. David Jin
    CFO & Head of Corp. Devel.
  • Mr. Samuel Berry
    Gen. Counsel & Corp. Sec.
  • Dr. Thomas F. Schaible
    Project Leader of Inflammatory Bowel Disease













FBIO Stock - Frequently Asked Questions

Should I buy or sell Fortress Biotech stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FBIO shares.
View FBIO analyst ratings
or view top-rated stocks.

What is Fortress Biotech's stock price forecast for 2023?

5 Wall Street analysts have issued 1 year price targets for Fortress Biotech's shares. Their FBIO share price forecasts range from $6.00 to $20.00. On average, they anticipate the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 1,210.3% from the stock's current price.
View analysts price targets for FBIO
or view top-rated stocks among Wall Street analysts.

How have FBIO shares performed in 2022?

Fortress Biotech's stock was trading at $2.50 at the beginning of the year. Since then, FBIO shares have decreased by 71.0% and is now trading at $0.7250.
View the best growth stocks for 2022 here
.

When is Fortress Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our FBIO earnings forecast
.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) announced its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.06. The biopharmaceutical company had revenue of $21.09 million for the quarter, compared to the consensus estimate of $18.41 million. Fortress Biotech had a negative net margin of 117.49% and a negative trailing twelve-month return on equity of 54.56%.

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Who are Fortress Biotech's major shareholders?

Fortress Biotech's stock is owned by many different institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (7.67%), Vanguard Group Inc. (4.74%), Tang Capital Management LLC (3.89%), Shikiar Asset Management Inc. (0.78%), Perkins Capital Management Inc. (0.74%) and Renaissance Technologies LLC (0.41%). Insiders that own company stock include Eric K Rowinsky, Lindsay A Md Rosenwald, Malcolm Hoenlein and Robyn Hunter.
View institutional ownership trends
.

How do I buy shares of Fortress Biotech?

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $0.73.

How much money does Fortress Biotech make?

Fortress Biotech (NASDAQ:FBIO) has a market capitalization of $78.11 million and generates $68.79 million in revenue each year. The biopharmaceutical company earns $-64,700,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

How many employees does Fortress Biotech have?

The company employs 173 workers across the globe.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.fortressbiotech.com. The biopharmaceutical company can be reached via phone at (781) 652-4500, via email at ir@fortressbiotech.com, or via fax at 781-652-4545.

This page (NASDAQ:FBIO) was last updated on 11/27/2022 by MarketBeat.com Staff